Hot Features
プレミアム
Artiva Biotherapeutics Inc (ARTV)
NASDAQ
登録してリアルタイムのチャート、分析ツール、価格を入手してください。
| 日付 | 保有者名 | 取引株数 | 金額レンジ ($) | 取引種別 | 価格レンジ ($) | 届出終了時の株数 | % 変化 |
|---|---|---|---|---|---|---|---|
| 2026-05-11 | GC Cell Corporation法人 | 1.43M | 16.50M | 買い | 11.52 | 6.00M | 31.36% |
| 2026-05-19 | Dr. Heather RaymonSVP of Research & Early Development | -3.10k | 27.88k | 売り | 9.01 | 148.23k | -2.05% |
| 2026-05-19 | Mr. Christopher P. HoranChief Technical Operations Officer | -7.00k | 63.07k | 売り | 9.01 | 293.45k | -2.33% |
| 2026-05-19 | Ms. Jennifer Kinsbruner BushCOO | -8.79k | 79.18k | 売り | 9.01 | 20.97k | -29.54% |
| 2026-05-19 | Dr. Subhashis BanerjeeChief Medical Officer | -7.04k | 63.39k | 売り | 9.01 | 144.96k | -4.63% |
| 2026-05-19 | Dr. Fred AslanCEO, Principal Financial & Accounting Officer and Director | -27.12k | 244.25k | 売り | 9.01 | 1.54M | -1.74% |
| 2026-05-11 | RA Capital Management, L.P.法人 | 6.51M | 75.00M | 買い | 11.52 | 15.20M | 74.89% |
| 2026-05-11 | RA Capital Management, L.P.法人 | 2.17M | 0.00 | Open Market Derivative Acquisition | 0.00 | 2.17M | - |
| 2026-05-11 | RA Capital Management, L.P.法人 | 6.51M | 75.00M | 買い | 11.52 | 68.32k | -101.06% |
| 2026-02-15 | Dr. Heather RaymonSVP of Research & Early Development | -1.52k | 6.08k | Sale to Issuer | 4.00 | 151.32k | -1.00% |
| 2026-02-15 | Mr. Christopher P. HoranChief Technical Operations Officer | -2.19k | 8.75k | Sale to Issuer | 4.00 | 300.45k | -0.72% |
| 2026-02-15 | Ms. Jennifer Kinsbruner BushCOO | -3.52k | 14.06k | Sale to Issuer | 4.00 | 26.63k | -11.66% |
| 2026-02-15 | Dr. Fred AslanCEO, Principal Financial & Accounting Officer and Director | -14.60k | 58.40k | Sale to Issuer | 4.00 | 1.56M | -0.93% |
| 2025-12-15 | Dr. Fred AslanCEO, Principal Financial & Accounting Officer and Director | -3.19k | 19.12k | Automatic Disposition | 6.00 | 1.21M | -0.26% |
| 2025-11-15 | Mr. Christopher P. HoranChief Technical Operations Officer | -1.90k | 6.17k | Sale to Issuer | 3.25 | 78.18k | -2.37% |
| 2025-11-15 | Dr. Heather RaymonSVP of Research & Early Development | -1.38k | 4.47k | Sale to Issuer | 3.25 | 39.59k | -3.36% |
| 2025-11-15 | Ms. Jennifer Kinsbruner BushCOO | -3.06k | 9.93k | Sale to Issuer | 3.25 | 18.84k | -13.95% |
| 2025-11-17 | Dr. Fred AslanCEO, Principal Financial & Accounting Officer and Director | -6.38k | 21.52k | Automatic Disposition | 3.38 | 344.00k | -1.82% |
| 2025-11-15 | Dr. Fred AslanCEO, Principal Financial & Accounting Officer and Director | -6.35k | 20.63k | Sale to Issuer | 3.25 | 344.00k | -1.81% |
| 2025-11-15 | Ms. Neha Krishnamohanインサイダー | -3.49k | 11.34k | Sale to Issuer | 3.25 | 19.36k | -15.28% |
| 2025-10-17 | Dr. Fred AslanCEO, Principal Financial & Accounting Officer and Director | -25.50k | 153.00k | Automatic Disposition | 6.00 | 356.72k | -6.67% |
| 2025-05-15 | Mr. Christopher P. HoranChief Technical Operations Officer | -4.92k | 12.69k | Sale to Issuer | 2.13 - 2.75 | 80.08k | -5.79% |
| 2025-05-15 | Ms. Neha Krishnamohanインサイダー | -7.15k | 18.84k | Sale to Issuer | 2.13 - 2.75 | 15.97k | -30.94% |
| 2025-05-15 | Dr. Fred AslanCEO, Principal Financial & Accounting Officer and Director | -8.94k | 21.82k | Sale to Issuer | 2.13 - 2.75 | 382.22k | -2.29% |
| 2025-05-15 | Dr. Heather RaymonSVP of Research & Early Development | -2.38k | 6.09k | Sale to Issuer | 2.13 - 2.75 | 40.97k | -5.50% |
| 2025-08-15 | Dr. Fred AslanCEO, Principal Financial & Accounting Officer and Director | -25.50k | 69.58k | Automatic Disposition | 2.73 | 382.22k | -6.25% |
| 2025-05-15 | Ms. Jennifer Kinsbruner BushCOO | -8.35k | 21.75k | Sale to Issuer | 2.13 - 2.75 | 14.45k | -36.61% |
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
メールアドレスで登録
すでにアカウントをお持ちですか？ サインイン
アカウントをお持ちでないですか？ 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。
